Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for selpercatinib in Relationship Comments (approximate match)

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Selpercatinib

CEGM9YBNGD

Search for Structure

Status:

US Approved Rx (2024)

Source:

NDA218160

(2024)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218160

First approved in 2020

Source:

NDA213246

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Proto-oncogene tyrosine-protein kinase receptor Ret

Conditions:

RET fusion-positive thyroid cancer

RET fusion-positive non-small cell lung cancer

RET-mutant medullary thyroid cancer

Selpercatinib (LOXO-292, ARRY-192) is a potent and specific RET (c-RET) inhibitor that was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.

PLASMA PROTEIN FRACTION (HUMAN)

6D53G0FD0Z

Status:

US Approved Rx (2013)

Source:

BLA125416

(2013)

Source URL:

https://www.fda.gov/media/113210/download

First approved in 1958

Source:

BLA101140

Source URL:

https://www.fda.gov/media/113210/download

Class:

MIXTURE

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET V804L

SWY4QNB42K

Subunit 1 (1086) Similarity Search

Sequence Search

Subunit 1 (1086) Similarity Search

Status:

Other

Class:

PROTEIN

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET V804M

N3H2YMZ2NH

Subunit 1 (1086) Similarity Search

Sequence Search

Subunit 1 (1086) Similarity Search

Status:

Other

Class:

PROTEIN

Structure of Selpercatinib

ACHIRAL

6D53G0FD0Z
Not a public record

Mixture

PLASMA PROTEIN FRACTION (HUMAN)

Protein

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET V804L

Protein

PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET V804M

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1